|
1
|
Davies L and Welch HG: Current thyroid
cancer trends in the United States. JAMA Otolaryngol Head Neck
Surg. 140:317–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hay ID, Thompson GB, Grant CS, Bergstralh
EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL,
et al: Papillary thyroid carcinoma managed at the Mayo Clinic
during six decades (1940–1999): Temporal trends in initial therapy
and long-term outcome in 2444 consecutively treated patients. World
J Surg. 26:879–885. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lam AK-Y, Lo C-Y and Lam KS-L: Papillary
carcinoma of thyroid: A 30-yr clinicopathological review of the
histological variants. Endocr Pathol. 16:323–330. 2005. View Article : Google Scholar
|
|
4
|
Shi X, Liu R, Basolo F, Giannini R, Shen
X, Teng D, Guan H, Shan Z, Teng W, Musholt TJ, et al: Differential
clinicopathological risk and prognosis of major papillary thyroid
cancer variants. J Clin Endocrinol Metab. 101:264–274. 2016.
View Article : Google Scholar :
|
|
5
|
Agrawal N, Akbani R, Aksoy BA, Ally A,
Arachchi H, Asa SL, Auman JT, Balasundaram M, Balu S, Baylin SB, et
al Cancer Genome Atlas Research Network: Integrated genomic
characterization of papillary thyroid carcinoma. Cell. 159:676–690.
2014. View Article : Google Scholar :
|
|
6
|
Lawrence MS, Stojanov P, Polak P, Kryukov
GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH,
Roberts SA, et al: Mutational heterogeneity in cancer and the
search for new cancer-associated genes. Nature. 499:214–218. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Elsheikh TM, Asa SL, Chan JKC, DeLellis
RA, Heffess CS, LiVolsi VA and Wenig BM: Interobserver and
intraobserver variation among experts in the diagnosis of thyroid
follicular lesions with borderline nuclear features of papillary
carcinoma. Am J Clin Pathol. 130:736–744. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ghossein R and Livolsi VA: Papillary
thyroid carcinoma tall cell variant. Thyroid. 18:1179–1181. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hall JS, Taylor J, Valentine HR, Irlam JJ,
Eustace A, Hoskin PJ, Miller CJ and West CM: Enhanced stability of
microRNA expression facilitates classification of FFPE tumour
samples exhibiting near total mRNA degradation. Br J Cancer.
107:684–694. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rosignolo F, Sponziello M, Giacomelli L,
Russo D, Pecce V, Biffoni M, Bellantone R, Lombardi CP, Lamartina
L, Grani G, et al: Identification of thyroid-associated serum
microRNA profiles and their potential use in thyroid cancer
follow-up. J Endocr Soc. 1:3–13. 2017.
|
|
13
|
Saiselet M, Pita JM, Augenlicht A, Dom G,
Tarabichi M, Fimereli D, Dumont JE, Detours V and Maenhaut C: miRNA
expression and function in thyroid carcinomas: A comparative and
critical analysis and a model for other cancers. Oncotarget.
7:52475–52492. 2016.PubMed/NCBI
|
|
14
|
Swierniak M, Wojcicka A, Czetwertynska M,
Stachlewska E, Maciag M, Wiechno W, Gornicka B, Bogdanska M,
Koperski L, de la Chapelle A, et al: In-depth characterization of
the microRNA transcriptome in normal thyroid and papillary thyroid
carcinoma. J Clin Endocrinol Metab. 98:E1401–E1409. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang Y, Liao D, Pan L, Ye R, Li X, Wang
S, Ye C and Chen L: Expressions of miRNAs in papillary thyroid
carcinoma and their associations with the BRAFV600E mutation. Eur J
Endocrinol. 168:675–681. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu Y, Wang H, Chen E, Xu Z, Chen B and Lu
G: Candidate microRNAs as biomarkers of thyroid carcinoma: A
systematic review, meta-analysis, and experimental validation.
Cancer Med. 5:2602–2614. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aragon Han P, Weng C-H, Khawaja HT,
Nagarajan N, Schneider EB, Umbricht CB, Witwer KW and Zeiger MA:
MicroRNA expression and association with clinicopathologic features
in papillary thyroid cancer: A systematic review. Thyroid.
25:1322–1329. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dettmer M, Perren A, Moch H, Komminoth P,
Nikiforov YE and Nikiforova MN: Comprehensive MicroRNA expression
profiling identifies novel markers in follicular variant of
papillary thyroid carcinoma. Thyroid. 23:1383–1389. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American Thyroid Association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The American Thyroid Association
guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar :
|
|
20
|
Rosignolo F, Maggisano V, Sponziello M,
Celano M, Di Gioia CR, D'Agostino M, Giacomelli L, Verrienti A,
Dima M, Pecce V, et al: Reduced expression of THRβ in papillary
thyroid carcinomas: Relationship with BRAF mutation, aggressiveness
and miR expression. J Endocrinol Invest. 38:1283–1289. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sponziello M, Lavarone E, Pegolo E, Di
Loreto C, Puppin C, Russo MA, Bruno R, Filetti S, Durante C, Russo
D, et al: Molecular differences between human thyroid follicular
adenoma and carcinoma revealed by analysis of a murine model of
thyroid cancer. Endocrinology. 154:3043–3053. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
R Development Core Team: R: A language and
environment for statistical computing. R Foundation for Statistical
Computing; Vienna: URL http://www.R-project.org/.
|
|
23
|
Wright SP: Adjusted P-values for
simultaneous inference. Biometrics. 48:1005–1013. 1992. View Article : Google Scholar
|
|
24
|
Pencheva N, Tran H, Buss C, Huh D,
Drobnjak M, Busam K and Tavazoie SF: Convergent multi-miRNA
targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis
and angiogenesis. Cell. 151:1068–1082. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dong W, Yao C, Teng X, Chai J, Yang X and
Li B: MiR-140–3p suppressed cell growth and invasion by
downregulating the expression of ATP8A1 in non-small cell lung
cancer. Tumour Biol. 37:2973–2985. 2016. View Article : Google Scholar
|
|
26
|
Liu R, Liu C, Zhang D, Liu B, Chen X,
Rycaj K, Jeter C, Calhoun-Davis T, Li Y, Yang T, et al: miR-199a-3p
targets stemness-related and mitogenic signaling pathways to
suppress the expansion and tumorigenic capabilities of prostate
cancer stem cells. Oncotarget. 7:56628–56642. 2016.PubMed/NCBI
|
|
27
|
Kinose Y, Sawada K, Nakamura K, Sawada I,
Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Takahashi K, Kurachi
H, et al: The hypoxia-related microRNA miR-199a-3p displays tumor
suppressor functions in ovarian carcinoma. Oncotarget.
6:11342–11356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Minna E, Romeo P, De Cecco L, Dugo M,
Cassinelli G, Pilotti S, Degl'Innocenti D, Lanzi C, Casalini P,
Pierotti MA, et al: miR-199a-3p displays tumor suppressor functions
in papillary thyroid carcinoma. Oncotarget. 5:2513–2528. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chou C-K, Chen R-F, Chou F-F, Chang HW,
Chen YJ, Lee YF, Yang KD, Cheng JT, Huang CC and Liu RT: miR-146b
is highly expressed in adult papillary thyroid carcinomas with high
risk features including extrathyroidal invasion and the BRAF
(V600E) mutation. Thyroid. 20:489–494. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mardente S, Mari E, Consorti F, Di Gioia
C, Negri R, Etna M, Zicari A and Antonaci A: HMGB1 induces the
overexpression of miR-222 and miR-221 and increases growth and
motility in papillary thyroid cancer cells. Oncol Rep.
28:2285–2289. 2012.PubMed/NCBI
|
|
31
|
Qiu YH, Wei YP, Shen NJ, Wang ZC, Kan T,
Yu WL, Yi B and Zhang YJ: miR-204 inhibits epithelial to
mesenchymal transition by targeting slug in intrahepatic
cholangiocarcinoma cells. Cell Physiol Biochem. 32:1331–1341. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mancikova V, Castelblanco E, Pineiro-Yanez
E, Perales-Paton J, de Cubas AA, Inglada-Perez L, Matias-Guiu X,
Capel I, Bella M, Lerma E, et al: MicroRNA deep-sequencing reveals
master regulators of follicular and papillary thyroid tumors. Mod
Pathol. 28:748–757. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Saiselet M, Gacquer D, Spinette A, Craciun
L, Decaussin-Petrucci M, Andry G, Detours V and Maenhaut C: New
global analysis of the microRNA transcriptome of primary tumors and
lymph node metastases of papillary thyroid cancer. BMC Genomics.
16:8282015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nikiforov YE, Seethala RR, Tallini G,
Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan
A, Kakudo K, et al: Nomenclature revision for encapsulated
follicular variant of papillary thyroid carcinoma: A paradigm shift
to reduce overtreatment of indolent tumors. JAMA Oncol.
2:1023–1029. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sheu S-Y, Grabellus F, Schwertheim S, Worm
K, Broecker-Preuss M and Schmid KW: Differential miRNA expression
profiles in variants of papillary thyroid carcinoma and
encapsulated follicular thyroid tumours. Br J Cancer. 102:376–382.
2010. View Article : Google Scholar :
|
|
36
|
Borrelli N, Denaro M, Ugolini C, Poma AM,
Miccoli M, Vitti P, Miccoli P and Basolo F: miRNA expression
profiling of 'noninvasive follicular thyroid neoplasms with
papillary-like nuclear features' compared with adenomas and
infiltrative follicular variants of papillary thyroid carcinomas.
Mod Pathol. 30:39–51. 2017. View Article : Google Scholar
|
